DE68917126T2 - T-zellen-epitope als träger für einen konjugierten impfstoff. - Google Patents

T-zellen-epitope als träger für einen konjugierten impfstoff.

Info

Publication number
DE68917126T2
DE68917126T2 DE68917126T DE68917126T DE68917126T2 DE 68917126 T2 DE68917126 T2 DE 68917126T2 DE 68917126 T DE68917126 T DE 68917126T DE 68917126 T DE68917126 T DE 68917126T DE 68917126 T2 DE68917126 T2 DE 68917126T2
Authority
DE
Germany
Prior art keywords
conjugates
support
epitopes
cell epitope
conjugated vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68917126T
Other languages
English (en)
Other versions
DE68917126D1 (de
Inventor
Garvin Bixler
Subramonia Pillai
Richard Insel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Application granted granted Critical
Publication of DE68917126D1 publication Critical patent/DE68917126D1/de
Publication of DE68917126T2 publication Critical patent/DE68917126T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)
DE68917126T 1988-02-01 1989-01-31 T-zellen-epitope als träger für einen konjugierten impfstoff. Expired - Fee Related DE68917126T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01
PCT/US1989/000388 WO1989006974A2 (en) 1988-02-01 1989-01-31 T-cell epitope as carriers molecule for conjugate vaccines

Publications (2)

Publication Number Publication Date
DE68917126D1 DE68917126D1 (de) 1994-09-01
DE68917126T2 true DE68917126T2 (de) 1995-02-02

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68917126T Expired - Fee Related DE68917126T2 (de) 1988-02-01 1989-01-31 T-zellen-epitope als träger für einen konjugierten impfstoff.

Country Status (10)

Country Link
EP (1) EP0399001B1 (de)
JP (1) JP2921574B2 (de)
AT (1) ATE109008T1 (de)
AU (1) AU634153B2 (de)
CA (2) CA1340956C (de)
DE (1) DE68917126T2 (de)
DK (1) DK174416B1 (de)
FI (1) FI104374B (de)
NO (1) NO179164C (de)
WO (1) WO1989006974A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
DE4192335C2 (de) * 1990-09-18 1996-02-08 Biotech Australia Pty Ltd T-Zell-Epitope
WO1993011157A1 (en) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
AU4580093A (en) * 1992-07-22 1994-02-14 Proteus Molecular Design Limited Polypeptide antigens of mycobacterium bovis
ATE174628T1 (de) * 1992-07-31 1999-01-15 Medeva Holdings Bv Expression rekombinanter fusionsproteine in attenuierten bakterien
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ATE215124T1 (de) * 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
WO1995024216A1 (en) * 1994-03-07 1995-09-14 Auckland Uniservices Limited Prevention of diabetes
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
DK1329226T3 (da) * 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
DK0895538T3 (da) 1996-04-19 2002-11-04 Us Gov Sec Health Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
AU2002231621A1 (en) 2000-11-09 2002-05-21 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
KR20110084906A (ko) 2008-10-10 2011-07-26 에라 바이오테크, 에스.에이. 면역원-특이적 면역보강제로서의 재조합 단백질체들
US9358302B2 (en) * 2009-03-23 2016-06-07 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
EP2418284A1 (de) 2010-08-13 2012-02-15 ERA Biotech, S.A. Polypeptidsequenzen zur Induzierung von Proteinkörpern
EP2870974A1 (de) * 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN112543649A (zh) 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
AU634153B2 (en) 1993-02-18
ATE109008T1 (de) 1994-08-15
NO902909D0 (no) 1990-06-29
CA1340958C (en) 2000-04-11
DK182990D0 (da) 1990-07-31
NO179164C (no) 1996-08-21
DK182990A (da) 1990-07-31
WO1989006974A2 (en) 1989-08-10
EP0399001A1 (de) 1990-11-28
NO179164B (no) 1996-05-13
JP2921574B2 (ja) 1999-07-19
FI104374B (fi) 2000-01-14
WO1989006974A3 (en) 1989-08-24
DK174416B1 (da) 2003-02-17
JPH03502691A (ja) 1991-06-20
NO902909L (no) 1990-08-27
CA1340956C (en) 2000-04-11
DE68917126D1 (de) 1994-09-01
AU3065489A (en) 1989-08-25
EP0399001B1 (de) 1994-07-27
FI903292A0 (fi) 1990-06-29

Similar Documents

Publication Publication Date Title
DE68917126T2 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
DK1089760T3 (da) Kunstige T-hjælpecelleepitoper som immunstimulatorer for syntetiske peptidimmunogener
IL104696A0 (en) Dual carrier immunogenic construct and a vaccine containing the same
IL115047A0 (en) Pneumococcal polysaccharide - recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
DE69839587D1 (de) Enterokokkus antigene und vakzine
GR3015791T3 (en) Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines.
DE3380053D1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
DE3585370D1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
ZA873922B (en) Method of preparation and use for feline leukemia virus antigens
CO5241277A1 (es) Vacuna
GB2314560A (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US

8339 Ceased/non-payment of the annual fee